Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Bose

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Nature Biomedical Engineering|December 14, 2023
Restoration of sensory feedback from the foot and reduction of phantom limb pain via closed-loop spinal cord stimulationAmeya C Nanivadekar, Rohit Bose, Bailey A Petersen, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Nature Biomedical Engineering|December 28, 2023
Publisher Correction: Restoration of sensory feedback from the foot and reduction of phantom limb pain via closed-loop spinal cord stimulationAmeya C Nanivadekar, Rohit Bose, Bailey A Petersen, et al.
JCO Precision Oncology|August 11, 2022
Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic RelevanceKoichi Ogura, Arielle Elkrief, Anita S Bowman, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Stochastically Emergent Tumors offer in vivo whole genome interrogation of cancer evolution from non-malignant precursorsRuhollah Moussavi-Baygi, Matthew J Ryan, Woogwang Sim, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
Cancer Research|October 17, 2022
The 5-Hydroxymethylcytosine Landscape of Prostate CancerMartin Sjöström, Shuang G Zhao, Samuel Levy, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Nature Biomedical Engineering|December 14, 2023
Restoration of sensory feedback from the foot and reduction of phantom limb pain via closed-loop spinal cord stimulationAmeya C Nanivadekar, Rohit Bose, Bailey A Petersen, et al.
Urologic Oncology|November 26, 2022
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracersDaniel H Kwon, Nonna Shakhnazaryan, David Shui, et al.
Nature Biomedical Engineering|December 28, 2023
Publisher Correction: Restoration of sensory feedback from the foot and reduction of phantom limb pain via closed-loop spinal cord stimulationAmeya C Nanivadekar, Rohit Bose, Bailey A Petersen, et al.
JCO Precision Oncology|August 11, 2022
Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic RelevanceKoichi Ogura, Arielle Elkrief, Anita S Bowman, et al.
The Lancet. Oncology|November 3, 2023
Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trialRahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of <i>TP53</i> and <i>MDM2</i> associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Stochastically Emergent Tumors offer in vivo whole genome interrogation of cancer evolution from non-malignant precursorsRuhollah Moussavi-Baygi, Matthew J Ryan, Woogwang Sim, et al.
Clinical Genitourinary Cancer|June 14, 2023
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab VedotinTanya Jindal, Li Zhang, Prianka Deshmukh, et al.
European Urology Oncology|December 21, 2024
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study DataTanya Jindal, Cindy Jiang, Omar Alhalabi, et al.
Cancer Research|October 17, 2022
The 5-Hydroxymethylcytosine Landscape of Prostate CancerMartin Sjöström, Shuang G Zhao, Samuel Levy, et al.
Pageof 5